Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Identification of cisplatin sensitizers through high-throughput combinatorial screening.

Sun Y, Jiang W, Lu W, Song M, Liu K, Chen P, Chang A, Ling J, Chiao PJ, Hu Y, Huang P.

Int J Oncol. 2018 Jun 19. doi: 10.3892/ijo.2018.4447. [Epub ahead of print]

PMID:
29956742
2.

EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis.

Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, Li Y, Verma IM, Chiao PJ, Lu Z.

Mol Cell. 2018 Jan 18;69(2):347. doi: 10.1016/j.molcel.2017.12.034. No abstract available.

3.

Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression.

Chen DL, Lu YX, Zhang JX, Wei XL, Wang F, Zeng ZL, Pan ZZ, Yuan YF, Wang FH, Pelicano H, Chiao PJ, Huang P, Xie D, Li YH, Ju HQ, Xu RH.

Theranostics. 2017 Oct 17;7(19):4836-4849. doi: 10.7150/thno.20942. eCollection 2017.

4.

TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.

Santoro R, Carbone C, Piro G, Chiao PJ, Melisi D.

Drug Resist Updat. 2017 Nov;33-35:36-42. doi: 10.1016/j.drup.2017.10.004. Epub 2017 Nov 3.

5.

SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.

Zhou H, Qin Y, Ji S, Ling J, Fu J, Zhuang Z, Fan X, Song L, Yu X, Chiao PJ.

Oncogene. 2018 Feb 15;37(7):912-923. doi: 10.1038/onc.2017.393. Epub 2017 Oct 23.

PMID:
29059173
6.

NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.

Zhuang Z, Li H, Lee H, Aguilar M, Gocho T, Ju H, Iida T, Ling J, Fu J, Wu M, Sun Y, Lu Y, Chiao PJ.

Cancer Lett. 2017 Dec 28;411:44-56. doi: 10.1016/j.canlet.2017.09.018. Epub 2017 Sep 23.

PMID:
28951128
7.

Inhibition of Pancreatic Cancer by RhIL1RA-Response.

Chiao PJ, Ling J, Fu J, Lu Y, Sun YC.

Clin Cancer Res. 2017 Jun 15;23(12):3224. doi: 10.1158/1078-0432.CCR-17-0083. No abstract available.

8.

Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.

Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH, Chiao PJ.

Nat Commun. 2017 Feb 24;8:14437. doi: 10.1038/ncomms14437.

9.

IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma.

Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua CY, Phillips LM, Ren H, Fleming JB, Wang H, Chiao PJ, Hao J, Zhang W.

Cancer Res. 2016 Nov 15;76(22):6543-6554. doi: 10.1158/0008-5472.CAN-16-0438. Epub 2016 Sep 22.

10.

Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.

Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.

Cancer Lett. 2016 Aug 28;379(1):1-11. doi: 10.1016/j.canlet.2016.05.024. Epub 2016 May 24.

PMID:
27233476
11.

Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors.

Kang Y, Roife D, Lee Y, Lv H, Suzuki R, Ling J, Rios Perez MV, Li X, Dai B, Pratt M, Truty MJ, Chatterjee D, Wang H, Thomas RM, Wang Y, Koay EJ, Chiao PJ, Katz MH, Fleming JB.

Clin Cancer Res. 2016 Oct 1;22(19):4934-4946. Epub 2016 Apr 28.

12.

FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer.

Ji S, Qin Y, Liang C, Huang R, Shi S, Liu J, Jin K, Liang D, Xu W, Zhang B, Liu L, Liu C, Xu J, Ni Q, Chiao PJ, Li M, Yu X.

Clin Cancer Res. 2016 Aug 1;22(15):3950-60. doi: 10.1158/1078-0432.CCR-15-2380. Epub 2016 Mar 16.

13.

MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma.

Sun L, Chua CYX, Tian W, Zhang Z, Chiao PJ, Zhang W.

J Genet Genomics. 2015 Oct 20;42(10):563-577. doi: 10.1016/j.jgg.2015.07.003. Epub 2015 Aug 6. Review.

PMID:
26554910
14.

IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.

Zhuang Z, Ju HQ, Aguilar M, Gocho T, Li H, Iida T, Lee H, Fan X, Zhou H, Ling J, Li Z, Fu J, Wu M, Li M, Melisi D, Iwakura Y, Xu K, Fleming JB, Chiao PJ.

Clin Cancer Res. 2016 Mar 15;22(6):1432-44. doi: 10.1158/1078-0432.CCR-14-3382. Epub 2015 Oct 23. Erratum in: Clin Cancer Res. 2017 Feb 1;23 (3):868.

15.

Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.

Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ, Xu RH.

J Pineal Res. 2016 Jan;60(1):27-38. doi: 10.1111/jpi.12285. Epub 2015 Oct 17.

PMID:
26445000
16.

Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer.

Wang P, Zhu CF, Ma MZ, Chen G, Song M, Zeng ZL, Lu WH, Yang J, Wen S, Chiao PJ, Hu Y, Huang P.

Oncotarget. 2015 Aug 28;6(25):21148-58.

17.

ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer.

Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H, Gao J, Zhang B, Xu W, Liu J, Liang D, Liu L, Liu C, Long J, Zhou H, Chiao PJ, Xu J, Ni Q, Gao D, Yu X.

Cell Res. 2015 May;25(5):561-73. doi: 10.1038/cr.2015.30. Epub 2015 Mar 10.

18.

Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.

Ju HQ, Gocho T, Aguilar M, Wu M, Zhuang ZN, Fu J, Yanaga K, Huang P, Chiao PJ.

Mol Cancer Ther. 2015 Mar;14(3):788-98. doi: 10.1158/1535-7163.MCT-14-0420. Epub 2014 Dec 19.

19.

An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis.

Carbone C, Piro G, Fassan M, Tamburrino A, Mina MM, Zanotto M, Chiao PJ, Bassi C, Scarpa A, Tortora G, Melisi D.

Oncotarget. 2015 May 30;6(15):13822-34.

20.

SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium.

Kang Y, Ling J, Suzuki R, Roife D, Chopin-Laly X, Truty MJ, Chatterjee D, Wang H, Thomas RM, Katz MH, Chiao PJ, Fleming JB.

PLoS One. 2014 Sep 29;9(9):e107948. doi: 10.1371/journal.pone.0107948. eCollection 2014.

21.

Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis.

Chang Z, Ju H, Ling J, Zhuang Z, Li Z, Wang H, Fleming JB, Freeman JW, Yu D, Huang P, Chiao PJ.

PLoS One. 2014 Jul 16;9(7):e101452. doi: 10.1371/journal.pone.0101452. eCollection 2014.

22.

Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells.

Bera A, Zhao S, Cao L, Chiao PJ, Freeman JW.

PLoS One. 2013 Dec 5;8(12):e82282. doi: 10.1371/journal.pone.0082282. eCollection 2013.

23.

A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth.

Zhang Y, Yang J, Cui X, Chen Y, Zhu VF, Hagan JP, Wang H, Yu X, Hodges SE, Fang J, Chiao PJ, Logsdon CD, Fisher WE, Brunicardi FC, Chen C, Yao Q, Fernandez-Zapico ME, Li M.

EMBO Mol Med. 2013 Sep;5(9):1322-34. doi: 10.1002/emmm.201302507. Epub 2013 Jul 16.

24.

Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells.

Chang Z, Li Z, Wang X, Kang Y, Yuan Y, Niu J, Wang H, Chatterjee D, Fleming JB, Li M, Abbruzzese JL, Chiao PJ.

Clin Cancer Res. 2013 Feb 1;19(3):549-59. doi: 10.1158/1078-0432.CCR-12-0032. Epub 2013 Jan 22.

25.

Desensitization of NFκB for overcoming chemoresistance of pancreatic cancer cells to TNF-α or paclitaxel.

Fujioka S, Son K, Onda S, Schmidt C, Scrabas GM, Okamoto T, Fujita T, Chiao PJ, Yanaga K.

Anticancer Res. 2012 Nov;32(11):4813-21.

PMID:
23155247
26.

Study human pancreatic cancer in mice: how close are they?

Zhang Y, Chen L, Yang J, Fleming JB, Chiao PJ, Logsdon CD, Li M.

Biochim Biophys Acta. 2013 Jan;1835(1):110-8. doi: 10.1016/j.bbcan.2012.11.001. Epub 2012 Nov 9. Review.

27.

EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.

Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, Li Y, Verma IM, Chiao PJ, Lu Z.

Mol Cell. 2012 Dec 14;48(5):771-84. doi: 10.1016/j.molcel.2012.09.028. Epub 2012 Nov 1. Erratum in: Mol Cell. 2018 Jan 18;69(2):347.

28.

Kras, Pten, NF-κB, and inflammation: dangerous liaisons.

Chiao PJ, Ling J.

Cancer Discov. 2011 Jul;1(2):103-5. doi: 10.1158/2159-8290.CD-11-0115.

29.

KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H, Liu J, Lemischka IR, Hung MC, Chiao PJ.

Cancer Cell. 2012 Jan 17;21(1):105-20. doi: 10.1016/j.ccr.2011.12.006.

30.

K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis.

Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P.

Cell Res. 2012 Feb;22(2):399-412. doi: 10.1038/cr.2011.145. Epub 2011 Aug 30.

31.

Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon A, Abbruzzese JL, Chiao PJ.

J Natl Cancer Inst. 2011 Aug 3;103(15):1190-204. doi: 10.1093/jnci/djr243. Epub 2011 Jul 8.

32.

Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D.

Clin Cancer Res. 2011 Sep 1;17(17):5822-32. doi: 10.1158/1078-0432.CCR-11-1185. Epub 2011 Jul 7.

33.

Disruption of the NF-κB/IκBα Autoinhibitory Loop Improves Cognitive Performance and Promotes Hyperexcitability of Hippocampal Neurons.

Shim DJ, Yang L, Reed JG, Noebels JL, Chiao PJ, Zheng H.

Mol Neurodegener. 2011 Jun 10;6:42. doi: 10.1186/1750-1326-6-42.

34.

Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter.

Peng B, Ling J, Lee AJ, Wang Z, Chang Z, Jin W, Kang Y, Zhang R, Shim D, Wang H, Fleming JB, Zheng H, Sun SC, Chiao PJ.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15193-8. doi: 10.1073/pnas.1005533107. Epub 2010 Aug 9.

35.

Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells.

Son K, Fujioka S, Iida T, Furukawa K, Fujita T, Yamada H, Chiao PJ, Yanaga K.

Anticancer Res. 2009 Oct;29(10):3995-4003.

36.

Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.

Melisi D, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, Sherman BM, Abbruzzese JL, Chiao PJ.

Clin Cancer Res. 2009 Oct 15;15(20):6367-77. doi: 10.1158/1078-0432.CCR-09-0910. Epub 2009 Oct 6.

37.

TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation.

Li Z, Chang Z, Chiao LJ, Kang Y, Xia Q, Zhu C, Fleming JB, Evans DB, Chiao PJ.

Cancer Res. 2009 Oct 1;69(19):7851-9. doi: 10.1158/0008-5472.CAN-08-4002. Epub 2009 Sep 22.

38.

14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.

Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, Yu D.

Cancer Cell. 2009 Sep 8;16(3):195-207. doi: 10.1016/j.ccr.2009.08.010.

39.

Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.

Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K.

Anticancer Res. 2009 Aug;29(8):3173-8.

40.

Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB.

Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, Evans DB, Chiao PJ.

Mol Cancer Res. 2009 May;7(5):624-33. doi: 10.1158/1541-7786.MCR-08-0201. Epub 2009 May 12.

41.

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ.

Mol Cancer Ther. 2008 Apr;7(4):829-40. doi: 10.1158/1535-7163.MCT-07-0337.

42.

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS.

Cancer Cell. 2007 Jul;12(1):66-80.

43.

Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models.

Xie X, Xia W, Li Z, Kuo HP, Liu Y, Li Z, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y, Lang JY, Evans DB, Chiao PJ, Abbruzzese JL, Hung MC.

Cancer Cell. 2007 Jul;12(1):52-65.

44.

Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.

Uwagawa T, Li Z, Chang Z, Xia Q, Peng B, Sclabas GM, Ishiyama S, Hung MC, Evans DB, Abbruzzese JL, Chiao PJ.

Cancer. 2007 May 15;109(10):2142-53.

45.

NF-kappa B as a target for cancer therapy.

Melisi D, Chiao PJ.

Expert Opin Ther Targets. 2007 Feb;11(2):133-44. Review.

PMID:
17227230
46.

Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors.

Niu J, Chang Z, Peng B, Xia Q, Lu W, Huang P, Tsao MS, Chiao PJ.

J Biol Chem. 2007 Mar 2;282(9):6001-11. Epub 2007 Jan 2.

47.

Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.

Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM.

J Biol Chem. 2007 Feb 9;282(6):3507-19. Epub 2006 Dec 11.

48.

In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer.

Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, Sarkar FH.

Int J Cancer. 2007 Feb 15;120(4):906-17. Erratum in: Int J Cancer. 2014 Apr 15;134(8):E4. Retraction in: Int J Cancer. 2016 Nov 1;139(9):2145-6.

49.

Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P.

Cancer Cell. 2006 Sep;10(3):241-52.

50.

Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells.

Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ, McConkey DJ, Gallick GE.

Angiogenesis. 2006;9(2):101-10. Epub 2006 Jul 27.

PMID:
16871430

Supplemental Content

Loading ...
Support Center